Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

Blood (2024) 144 (Supplement 1): 3034.

https://doi.org/10.1182/blood-2024-201730

Published: 2024

Journal Articles

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Alexandra E. Rojek, Nausheen Ahmed, Marina Gomez Llobell, Sairah Ahmed, Marie Hu, Monica Mead, Andy Chen, Vivek Patel, Jamie Brower, Veronika Bachanova, Richard T. Maziarz, Olalekan O. Oluwole, Michael R Bishop, David L. Porter, Miguel Angel Perales, Joseph P. McGuirk, Peter A. Riedell, Daniel J. Landsburg

Blood (2024) 144 (Supplement 1): 4503.

https://doi.org/10.1182/blood-2024-198153

Published: 2024

Journal Articles

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Peter A. Riedell, Miguel-Angel Perales, Richard T Maziarz, Jamie Brower, Gunjan L. Shah, Andy Chen, Olalekan O. Oluwole, Stephen J Schuster, Michael R. Bishop, Joseph P McGuirk, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 4887.

https://doi.org/10.1182/blood-2023-182837

Published: 2023

Journal Articles

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Peter A Riedell, Connor Grady, Loretta J. Nastoupil, Alejandro Luna, Nausheen Ahmed, Richard T Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J Schuster, Andy Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter

Blood (2023) 142 (Supplement 1): 617.

https://doi.org/10.1182/blood-2023-184862

Published: 2023

Journal Articles

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2416.

https://doi.org/10.1182/blood-2023-187524

Published: 2023

Journal Articles

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Somya Khare, Staci Williamson, Brittany O'Barr, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Jessica T. Leonard, Amrita Desai, Peter Ferreira-Gandolfo, Denise Lackey, Kevin Christmas, Richard T Maziarz, Eneida R Nemecek

Blood (2023) 142 (Supplement 1): 2405.

https://doi.org/10.1182/blood-2023-177864

Published: 2023

Journal Articles

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Blood (2023) 142 (Supplement 1): 601.

https://doi.org/10.1182/blood-2023-180936

Published: 2023

Journal Articles

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Blood (2022) 140 (Supplement 1): 1459–1463.

https://doi.org/10.1182/blood-2022-158024

Published: 2022

Journal Articles

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Arthur Nguyen, Joseph S Bubalo, Jennifer N. Saultz, Brandon Hayes-Lattin, Andy Chen, Rachel J. Cook, Arpita Gandhi, Jessica Leonard, Richard T. Maziarz, Yazan Migdady, Eneida R. Nemecek, Levanto Schachter

Blood (2022) 140 (Supplement 1): 12856–12858.

https://doi.org/10.1182/blood-2022-156011

Published: 2022

Journal Articles

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Shakthi Bhaskar, Vivek Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 10971–10973.

https://doi.org/10.1182/blood-2022-155886

Published: 2022

Journal Articles

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Vivek Patel, Shakthi Bhaskar, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Roni Shouval, Joseph P. McGuirk, Richard T. Maziarz, Andy Chen, Veronika Bachanova, David L. Porter, Michael R. Bishop, Peter A. Riedell, Olalekan O. Oluwole

Blood (2022) 140 (Supplement 1): 366–368.

https://doi.org/10.1182/blood-2022-165556

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Blood (2021) 138 (Supplement 1): 131.

https://doi.org/10.1182/blood-2021-145025

Published: 2021

Journal Articles

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Nathan H. Fowler, Michael Dickinson, Monalisa Ghosh, Andy Chen, Charalambos Andreadis, Ranjan Tiwari, Aisha Masood, Roberto Ramos, Vamsi Bollu, Etienne Jousseaume, Catherine Thieblemont, Martin H. Dreyling, Stephen J. Schuster

Blood (2021) 138 (Supplement 1): 3533.

https://doi.org/10.1182/blood-2021-145741

Published: 2021

Journal Articles

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

Derek Galligan, MD, Staci Williamson, MS, Jessie Myers, Rebecca W. Silbermann, MD, Eva Medvedova, MD, Levanto Schachter, DO,MS, Sarah J. Nagle, MD, Andy Chen, MDPhD, Richard T. Maziarz, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-142770

Published: 2020

Journal Articles

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

Jae H. Park, MD, Nitin Jain, MD, Andy Chen, MDPhD, Joseph P. McGuirk, DO, Monica Diaz, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Januario E. Castro, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142423

Published: 2020

Journal Articles

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Taylor Rowland, Cody Paiva, BS, Joelle Rowley, Andy Chen, MD PhD, Lisa Drew, PhD, Peter Hurlin, Bill H. Chang, MD PhD, Alexey V Danilov, MD PhD

Blood (2016) 128 (22): 289.

https://doi.org/10.1182/blood.V128.22.289.289

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Hervé Tilly, MD PhD, Franck Morschhauser, Nancy L Bartlett, MD, Jeff Sharman, MD, Corinne Haioun, MD PhD, Kathryn S. Kolibaba, Andy Chen, DO, Thierry Lamy, MD PhD, Surai Jones, MS Biostat, Elicia Penuel, PhD, Calvin Lee, Gilles A. Salles

Blood (2016) 128 (22): 1853.

https://doi.org/10.1182/blood.V128.22.1853.1853

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Tycel Phillips, MD, Mark Brunvand, MD, Andy Chen, MD PhD, Oliver Press, MD PhD, James Essell, MD, Annalisa Chiappella, MD, Catherine Diefenbach, MD, Surai Jones, MS Biostat, Jamie Hirata, PharmD, Ian W. Flinn, MD PhD

Blood (2016) 128 (22): 622.

https://doi.org/10.1182/blood.V128.22.622.622

Published: 2016

NARROW

Clinical Outcomes of Patients with High-Risk Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 ELARA 4-Year Update

CAR T Cell Therapy in Early Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

“Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel and Tisagenlecleucel”

Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium

Access and Outcomes of Minority Health Populations Receiving Commercial Anti-CD19 CART Therapy for Non-Hodgkin Lymphoma

Access to Chimeric Antigen T-Cell Receptor (CAR-T) Therapies for Patients with Non-Hodgkin Lymphoma (NHL) in the Catchment Area of Oregon

Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up

Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Breakthrough CMV Viremia Outcomes of Letermovir Prophylaxis in Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide

Cytokine Release Syndrome (CRS) Is Not Required for CAR-T Cell Efficacy in Aggressive Large B-NHL

Predictors and Outcomes of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Aggressive B-Cell Non-Hodgkin Lymphoma

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High-Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase II Elara Study

Assessment of Healthcare Resource Utilization and Costs in Patients with Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study

Second Autologous Stem Cell Transplant As Salvage Therapy in Multiple Myeloma - the Oregon Health and Science University Experience

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells

Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study

Polatuzumab Vedotin Combined with Obinutuzumab for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma: Preliminary Safety and Clinical Activity of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only